Effectiveness and safety of didanosine, lamivudine and efavirenz versus zidovudine, lamivudine and efavirenz for the initial treatment of HIV-infected patients from the Spanish VACH cohort
Author(s) -
Manuel Crespo,
Esteban Ribera,
Ignacio Suárez-Lozano,
Peré Domingo,
Enric Pedrol,
José LópezAldeguer,
Agustín Matías Muñoz,
Consuelo Viladés,
T Sánchez,
Pompeyo Viciana,
Ramón Teira,
Ma Luisa Garcia-Alcalde,
A. Vergara,
Fernando Lozano,
MJ Galindo,
J. Cosin,
Bernardino Roca,
A. Terrón,
Paloma Geijo,
Francesc Vidal,
Myriam Garrido
Publication year - 2008
Publication title -
journal of antimicrobial chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.124
H-Index - 194
eISSN - 1460-2091
pISSN - 0305-7453
DOI - 10.1093/jac/dkn450
Subject(s) - efavirenz , lamivudine , didanosine , zidovudine , medicine , stavudine , gastroenterology , viral load , virology , viral disease , human immunodeficiency virus (hiv) , antiretroviral therapy , virus , hepatitis b virus
Preliminary data suggest that a once-daily combination of lamivudine, didanosine and efavirenz is an effective alternative regimen for antiretroviral-naive HIV-1-infected patients. However, data from randomized trials comparing this combination versus standard first-line regimens are not available yet. In an observational study, we analyse the efficacy and tolerability of didanosine plus lamivudine and efavirenz versus zidovudine plus lamivudine and efavirenz in a cohort of therapy naive patients.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom